80_FR_14193 80 FR 14141 - Government-Owned Inventions; Availability for Licensing

80 FR 14141 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 52 (March 18, 2015)

Page Range14141-14142
FR Document2015-06123

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 80 Issue 52 (Wednesday, March 18, 2015) 
[Federal Register Volume 80, Number 52 (Wednesday, March 18, 2015)]
[Notices]
[Pages 14141-14142]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-06123]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

GTF2I Mutations as Genetic Marker for Prognosis of Thymic Malignancies

    Description of Technology: The present invention describes the 
presence of a mutation in the general transcription factor IIi (GTF2I) 
gene in indolent thymic tumors that is rarely found in more aggressive 
thymic tumors.
    The invention provides a method of determining the prognosis of 
thymic cancer in a patient by assaying (for example using PCR based 
methods) the genetic material obtained from the patient tissue to 
detect a mutation in at least one copy of GTF2I genetic sequence; and 
correlating the presence of a GTF2I mutation with the prognosis of a 
thymic cancer patient, the presence of the mutation indicating that the 
thymic cancer is indolent.
    A genetic test will complement the diagnostic assessment, 
facilitate development of a molecular classification and assessment for 
the clinical management of thymic cancers.
    Potential Commercial Applications:
     A diagnostic test kit for the prognosis and clinical 
management of thymic cancer.
     Clinical decision whether treatment is needed (for 
example, additional treatment after surgery).
     Therapeutic decision making, between an aggressive course 
of

[[Page 14142]]

treatment for more aggressive cancers versus non aggressive treatment.
    Competitive Advantages: The PCR based method is more advantageous 
and more objective than currently available histological classification 
and staging systems.
    Development Stage:
     Early-stage.
     In vitro data available.
     In vivo data available (human).
    Inventors: Guiseppe Giaccone and Yisong Wang (NCI).
    Publication: Petrini I, et al. A specific missense mutation in 
GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 
2014 Aug;46(8):844-9. [PMID 24974848].
    Intellectual Property: HHS Reference No. E-109-2014/0--US 
Provisional Application No. 61/975,222 filed April 4, 2014.
    Licensing Contact: Sabarni Chatterjee, Ph.D., MBA; 301-435-5587; 
chatterjeesa@mail.nih.gov.
    Collaborative Research Opportunity: For collaboration 
opportunities, please contact Dr. Guiseppe Giaccone at 
gg496@georgetown.edu.

Systems and Devices for Training and Imaging an Awake Test Animal

    Description of Technology: The invention pertains to an apparatus 
and training system for rodents to maintain its head substantially 
motionless during an imaging procedure. The system includes a frame 
defining an enclosure for enclosing an animal therein during the 
imaging procedure which has a head post attached to the head of the 
animal and a treadmill having a plurality of rollers that the animal 
walks on such that one or more of the plurality of wheels rotate when 
the animal is in walking motion and stop rotating when the animal is in 
a substantially motionless state. This arrangement trains the animal to 
remain substantially motionless when disposed within an imaging 
apparatus. This invention permits prolonged imaging of awake rodents 
with minimal confinement and reduces stress.
    Potential Commercial Applications:
     Imaging test rodents.
     Imaging pharmacological agent distribution in rodents.
     Imaging the therapeutically effects of pharmacological 
agent.
    Competitive Advantages: Imaging while animal is awake.
    Development Stage:
     Early-stage.
     Prototype.
    Inventors: Hanbing Lu, Yihong Yang, Elliot Stein (all of NIDA).
    Intellectual Property: HHS Reference No. E-043-2015/0--US Patent 
Application 14/589,725 filed January 5, 2015.
    Licensing Contact: Michael Shmilovich; 301-435-5019; 
shmilovm@mail.nih.gov.
    Collaborative Research Opportunity: The National Institute on Drug 
Abuse is seeking statements of capability or interest from parties 
interested in collaborative research to further develop apparatus and/
or the training system; commercialize with pharmaceutical industry. For 
collaboration opportunities, please contact Vio Conley, M.S. at 
conleyv@mail.nih.gov.

Miniature System for Manipulating Small Animals in High-Throughput 
Screening Small Molecules

    Description of Technology: The invention pertains to a miniaturized 
plating and feeding system based on a 96-well microplate base and is 
intended to reduce manipulation of organisms as well as amounts of test 
drug/anesthetic, thereby mitigating waste. The kit comprises a feeder 
plate, transfer adaptor and receiver plate. The feeder plate is defined 
by, for example, a plastic 96-well plate with rounded wells. The 
rounded bottoms can dispense to or permit access to the test organism 
of liquid food or drug through about 7 holes of approximately 350 
microns in diameter. A top portion of the well provides test organisms 
(e.g., drosophila, daphnia) with sufficient space to enjoy normal life-
cycles without confinement stress. The feeder plate includes means for 
interfacing with complementary components of the transfer and receiver 
plates through receiving holes and complementary dowels or pins. A 
transfer adapter allows the interconnection of the feeder plate to the 
receiver plate. The transfer plate can be configured to be square or 
rounded for the transfer of organisms from the feeder plate to the 
receiver plate.
    Potential Commercial Applications:
     Drug Development.
     Toxicity Studies.
     Drug Design.
    Competitive Advantages:
     Small animals.
     High Throughput.
     Space efficiency.
     Resource economy.
    Development Stage:
     Early stage.
     Prototype.
    Inventors: Maria De Los Angeles Jaime and Brian Oliver (NIDDK).
    Intellectual Property: HHS Reference No. E-034-2015/0--US 
Provisional Application No. 62/080,181 filed November 14, 2014.
    Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019; 
shmilovm@mail.nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Diabetes and Digestive and Kidney Diseases is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize High-Throughput 
Small Animal Manipulation for Drug Design. For collaboration 
opportunities, please contact Marguerite J. Miller at 
millermarg@niddk.nih.gov.
    This abstract replaces one published on Thursday, January 29, 2015 
(80 FR 4935) to correct the patent application filing date.

    Dated: March 12, 2015.
Richard U. Rodriguez, M.B.A.,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-06123 Filed 3-17-15; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 80, No. 52 / Wednesday, March 18, 2015 / Notices 14141 information collection. This is a one- for managing patients with chronic voluntary and all responses CDC will time data collection effort. conditions and to improve the quality of de-identify all responses. There are no CDC will use the information to care delivered. NCHS and CDC will also costs to respondents other than their examine health systems and use the results to improve technical time. The total estimated annualized dissemination of health systems assistance to public health partners. burden hours are 429. technology. Primary care practices will OMB approval is requested for two use the results to inform their systems years. Participation in the survey is ESTIMATED ANNUALIZED BURDEN HOURS Average Number Number of burden per Type of respondent Form name responses per respondents response respondent (in hours) Physician ......................................................... Cognitive Testing Screener ............................ 25 1 5/60 Physician ......................................................... Cognitive Testing Protocol ............................. 15 1 1.25 Medical Secretary ........................................... NSPCP Screener ........................................... 1,500 1 10/60 Physician ......................................................... NSPCP ........................................................... 473 1 20/60 Leroy A. Richardson, Arthritis & Musculoskeletal and Skin may be obtained by writing to the Chief, Information Collection Review Office, Diseases, Building 10, Room 9N228, MSC indicated licensing contact at the Office Office of Scientific Integrity, Office of the 1820, Bethesda, MD 20892, (301) 496–2612, of Technology Transfer, National Associate Director for Science, Office of the osheaj@arb.niams.nih.gov. Institutes of Health, 6011 Executive Director, Centers for Disease Control and Any interested person may file written Boulevard, Suite 325, Rockville, Prevention. comments with the committee by forwarding Maryland 20852–3804; telephone: 301– [FR Doc. 2015–06159 Filed 3–17–15; 8:45 am] the statement to the Contact Person listed on this notice. The statement should include the 496–7057; fax: 301–402–0220. A signed BILLING CODE 4163–18–P Confidential Disclosure Agreement will name, address, telephone number and when applicable, the business or professional be required to receive copies of the affiliation of the interested person. patent applications. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Catalogue of Federal Domestic Assistance SUPPLEMENTARY INFORMATION: Program Nos. 93.846, Arthritis, Technology descriptions follow. National Institutes of Health Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS). GTF2I Mutations as Genetic Marker for National Institute of Arthritis and Dated: March 12, 2015. Prognosis of Thymic Malignancies Musculoskeletal and Skin Diseases; Carolyn Baum, Description of Technology: The Notice of Closed Meeting Program Analyst, Office of Federal Advisory present invention describes the Pursuant to section 10(d) of the Committee Policy. presence of a mutation in the general Federal Advisory Committee Act, as [FR Doc. 2015–06122 Filed 3–17–15; 8:45 am] transcription factor IIi (GTF2I) gene in amended (5 U.S.C. App.), notice is BILLING CODE 4140–01–P indolent thymic tumors that is rarely hereby given of a meeting of the Board found in more aggressive thymic of Scientific Counselors, NIAMS. tumors. The meeting will be closed to the DEPARTMENT OF HEALTH AND The invention provides a method of public as indicated below in accordance HUMAN SERVICES determining the prognosis of thymic with the provisions set forth in section cancer in a patient by assaying (for 552b(c)(6), Title 5 U.S.C., as amended National Institutes of Health example using PCR based methods) the for the review, discussion, and genetic material obtained from the Government-Owned Inventions; patient tissue to detect a mutation in at evaluation of individual intramural Availability for Licensing programs and projects conducted by the least one copy of GTF2I genetic National Institute of Arthritis and AGENCY: National Institutes of Health, sequence; and correlating the presence Musculoskeletal and Skin Diseases, HHS. of a GTF2I mutation with the prognosis including consideration of personnel ACTION: Notice. of a thymic cancer patient, the presence qualifications and performance, and the of the mutation indicating that the competence of individual investigators, SUMMARY: The inventions listed below thymic cancer is indolent. the disclosure of which would are owned by an agency of the U.S. A genetic test will complement the constitute a clearly unwarranted Government and are available for diagnostic assessment, facilitate invasion of personal privacy. licensing in the U.S. in accordance with development of a molecular 35 U.S.C. 209 and 37 CFR part 404 to classification and assessment for the Name of Committee: Board of Scientific Counselors, NIAMS. achieve expeditious commercialization clinical management of thymic cancers. Date: April 15–16, 2015. of results of federally-funded research Potential Commercial Applications: and development. Foreign patent • A diagnostic test kit for the mstockstill on DSK4VPTVN1PROD with NOTICES Time: 6:00 p.m. to 3:45 p.m. Agenda: To review and evaluate personal applications are filed on selected prognosis and clinical management of qualifications and performance, and inventions to extend market coverage thymic cancer. competence of individual investigators. for companies and may also be available • Clinical decision whether treatment Place: National Institutes of Health, for licensing. Building 31, Room 4C32, 31 Center Drive, is needed (for example, additional Bethesda, MD 20892. FOR FURTHER INFORMATION CONTACT: treatment after surgery). Contact Person: John J. O’Shea, MD, Ph.D., Licensing information and copies of the • Therapeutic decision making, Scientific Director, National Institute of U.S. patent applications listed below between an aggressive course of VerDate Sep<11>2014 19:00 Mar 17, 2015 Jkt 235001 PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 E:\FR\FM\18MRN1.SGM 18MRN1

14142 Federal Register / Vol. 80, No. 52 / Wednesday, March 18, 2015 / Notices treatment for more aggressive cancers Application 14/589,725 filed January 5, Licensing Contact: Michael versus non aggressive treatment. 2015. Shmilovich, Esq.; 301–435–5019; Competitive Advantages: The PCR Licensing Contact: Michael shmilovm@mail.nih.gov. based method is more advantageous and Shmilovich; 301–435–5019; shmilovm@ Collaborative Research Opportunity: more objective than currently available mail.nih.gov. The National Institute of Diabetes and histological classification and staging Collaborative Research Opportunity: Digestive and Kidney Diseases is systems. The National Institute on Drug Abuse is seeking statements of capability or Development Stage: seeking statements of capability or interest from parties interested in • Early-stage. interest from parties interested in collaborative research to further • In vitro data available. collaborative research to further develop develop, evaluate or commercialize • In vivo data available (human). apparatus and/or the training system; High-Throughput Small Animal Inventors: Guiseppe Giaccone and commercialize with pharmaceutical Manipulation for Drug Design. For Yisong Wang (NCI). industry. For collaboration collaboration opportunities, please Publication: Petrini I, et al. A specific opportunities, please contact Vio contact Marguerite J. Miller at missense mutation in GTF2I occurs at Conley, M.S. at conleyv@mail.nih.gov. millermarg@niddk.nih.gov. high frequency in thymic epithelial tumors. Nat Genet. 2014 Aug;46(8):844– Miniature System for Manipulating This abstract replaces one published 9. [PMID 24974848]. Small Animals in High-Throughput on Thursday, January 29, 2015 (80 FR Intellectual Property: HHS Reference Screening Small Molecules 4935) to correct the patent application No. E–109–2014/0—US Provisional filing date. Description of Technology: The Application No. 61/975,222 filed April invention pertains to a miniaturized Dated: March 12, 2015. 4, 2014. plating and feeding system based on a Richard U. Rodriguez, M.B.A., Licensing Contact: Sabarni Chatterjee, 96-well microplate base and is intended Acting Director, Office of Technology Ph.D., MBA; 301–435–5587; to reduce manipulation of organisms as Transfer, National Institutes of Health. chatterjeesa@mail.nih.gov. well as amounts of test drug/anesthetic, [FR Doc. 2015–06123 Filed 3–17–15; 8:45 am] Collaborative Research Opportunity: thereby mitigating waste. The kit BILLING CODE 4140–01–P For collaboration opportunities, please comprises a feeder plate, transfer contact Dr. Guiseppe Giaccone at adaptor and receiver plate. The feeder gg496@georgetown.edu. plate is defined by, for example, a DEPARTMENT OF HEALTH AND Systems and Devices for Training and plastic 96-well plate with rounded HUMAN SERVICES Imaging an Awake Test Animal wells. The rounded bottoms can dispense to or permit access to the test National Institutes of Health Description of Technology: The organism of liquid food or drug through invention pertains to an apparatus and Center for Scientific Review; Notice of about 7 holes of approximately 350 training system for rodents to maintain Closed Meetings microns in diameter. A top portion of its head substantially motionless during the well provides test organisms (e.g., Pursuant to section 10(d) of the an imaging procedure. The system drosophila, daphnia) with sufficient Federal Advisory Committee Act, as includes a frame defining an enclosure space to enjoy normal life-cycles amended (5 U.S.C. App.), notice is for enclosing an animal therein during without confinement stress. The feeder hereby given of the following meetings. the imaging procedure which has a head plate includes means for interfacing post attached to the head of the animal The meetings will be closed to the with complementary components of the and a treadmill having a plurality of public in accordance with the transfer and receiver plates through rollers that the animal walks on such provisions set forth in sections receiving holes and complementary that one or more of the plurality of 552b(c)(4) and 552b(c)(6), title 5 U.S.C., dowels or pins. A transfer adapter wheels rotate when the animal is in as amended. The grant applications and allows the interconnection of the feeder walking motion and stop rotating when the discussions could disclose plate to the receiver plate. The transfer the animal is in a substantially confidential trade secrets or commercial plate can be configured to be square or motionless state. This arrangement property such as patentable material, rounded for the transfer of organisms trains the animal to remain substantially and personal information concerning from the feeder plate to the receiver motionless when disposed within an individuals associated with the grant plate. imaging apparatus. This invention applications, the disclosure of which Potential Commercial Applications: permits prolonged imaging of awake would constitute a clearly unwarranted • Drug Development. rodents with minimal confinement and invasion of personal privacy. • Toxicity Studies. reduces stress. Potential Commercial Applications: • Drug Design. Name of Committee: Center for Scientific Competitive Advantages: Review Special Emphasis Panel; PAR Panel: • Imaging test rodents. Cancer Health Disparities/Diversity in Basic • Imaging pharmacological agent • Small animals. Cancer Research. distribution in rodents. • High Throughput. Date: April 13–14, 2015. • Imaging the therapeutically effects • Space efficiency. Time: 8:00 a.m. to 5:00 p.m. of pharmacological agent. • Resource economy. Agenda: To review and evaluate grant Competitive Advantages: Imaging Development Stage: applications. • Early stage. Place: Embassy Suites at the Chevy Chase mstockstill on DSK4VPTVN1PROD with NOTICES while animal is awake. Development Stage: • Prototype. Pavilion, 4300 Military Road, NW., Washington, DC 20015. • Early-stage. Inventors: Maria De Los Angeles Jaime Contact Person: Nywana Sizemore, Ph.D., • Prototype. and Brian Oliver (NIDDK). Scientific Review Officer, Center for Inventors: Hanbing Lu, Yihong Yang, Intellectual Property: HHS Reference Scientific Review, National Institutes of Elliot Stein (all of NIDA). No. E–034–2015/0—US Provisional Health, 6701 Rockledge Drive, Room 6204, Intellectual Property: HHS Reference Application No. 62/080,181 filed MSC 7804, Bethesda, MD 20892, 301–435– No. E–043–2015/0—US Patent November 14, 2014. 1718, sizemoren@csr.nih.gov. VerDate Sep<11>2014 19:00 Mar 17, 2015 Jkt 235001 PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 E:\FR\FM\18MRN1.SGM 18MRN1


Document Created: 2018-02-21 09:39:41
Document Modified: 2018-02-21 09:39:41
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402- 0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
FR Citation80 FR 14141 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR